A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John Daniel Hainsworth; Stefan Madajewicz; Thomas Michael Cosgriff; Kristen Pierce; Huiping Xu; Katherine Liau; Diane Healey

doi:10.1007/s00280-006-0352-0

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-006-0352-0 ◽

2006 ◽

Vol 60 (1) ◽

pp. 81-89 ◽

Cited By ~ 11

Author(s):

Roger B. Cohen ◽

Corey J. Langer ◽

George Rajan Simon ◽

Peter David Eisenberg ◽

John Daniel Hainsworth ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

Open Label Trial ◽

First Line Treatment

Download Full-text

6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71336-8 ◽

2007 ◽

Vol 5 (4) ◽

pp. 358-359

Author(s):

L. Paz-Ares ◽

M.N. Pollak ◽

P.D. Eisenberg ◽

L.J. Blakely ◽

P. Haluska ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Randomized Phase Ii ◽

Open Label Trial ◽

First Line Treatment

Download Full-text

PD3-3-1: A phase Ib/randomized phase II, non-comparative, open label trial of paclitaxel and carboplatin with or without the anti-IGF-IR antibody CP-751,871 as first-line treatment for advanced non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283411.38367.97 ◽

2007 ◽

Vol 2 (8) ◽

pp. S466

Author(s):

Daniel D. Karp ◽

L.G. Paz-Ares ◽

M.N. Pollak ◽

P.D. Eisenberg ◽

L.J. Blakely ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Ib ◽

Randomized Phase Ii ◽

Open Label Trial ◽

First Line Treatment

Download Full-text

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8056 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8056-8056

Author(s):

Masayuki Takeda ◽

Takashi Seto ◽

Hidetoshi Hayashi ◽

Morihito Okada ◽

Koichi Azuma ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(16)30250-7 ◽

2016 ◽

Vol 11 (4) ◽

pp. S117-S118 ◽

Cited By ~ 3

Author(s):

K. Park ◽

E.-H. Tan ◽

L. Zhang ◽

V. Hirsh ◽

K. O'Byrne ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Trial ◽

First Line Treatment

Download Full-text

An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdz063.078 ◽

2019 ◽

Vol 30 ◽

pp. ii65-ii66 ◽

Cited By ~ 1

Author(s):

J. Spicer ◽

M. Provencio ◽

P. Garrido Lopez ◽

J. Bosch-Barrera ◽

F.J. de Castro Carpeño ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Treatment

Download Full-text

An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000005 ◽

2013 ◽

Vol 8 (12) ◽

pp. 1529-1537 ◽

Cited By ~ 24

Author(s):

Giorgio V. Scagliotti ◽

Enriqueta Felip ◽

Benjamin Besse ◽

Joachim von Pawel ◽

Anders Mellemgaard ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Advanced Stage ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Phase I Study of Apatinib in Combination with Gefitinib As First-Line Treatment in Patients with EGFR-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer

SSRN Electronic Journal ◽

10.2139/ssrn.3454715 ◽

2019 ◽

Author(s):

Zhonghan Zhang ◽

Yang Zhang ◽

Fan Luo ◽

Yuxiang Ma ◽

Wenfeng Fang ◽

...

Keyword(s):

Lung Cancer ◽

Phase I ◽

Small Cell Lung Cancer ◽

Phase I Study ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

Lung Cancer ◽

10.1016/s0169-5002(16)30086-1 ◽

2016 ◽

Vol 91 ◽

pp. S25

Author(s):

K.J. O'Byrne ◽

K. Park ◽

E. Tan ◽

L. Zhang ◽

V. Hirsh ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Annals of Oncology ◽

10.1016/j.annonc.2020.10.479 ◽

2021 ◽

Vol 32 (1) ◽

pp. 85-96 ◽

Cited By ~ 1

Author(s):

M. Shi ◽

A. Gu ◽

H. Tu ◽

C. Huang ◽

H. Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text